<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790608</url>
  </required_header>
  <id_info>
    <org_study_id>CTP 5</org_study_id>
    <secondary_id>EudraCT 2008-001287-36</secondary_id>
    <nct_id>NCT00790608</nct_id>
  </id_info>
  <brief_title>Clinical Trial on the Reduction of Methicillin Resistant Staphylococcus Aureus (MRSA)</brief_title>
  <official_title>A Phase II Trial on the Reduction of Methicillin Resistant Staphylococcus Aureus in MRSA Positive Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nitric BioTherapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nitric BioTherapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if topically applied nitric oxide gas is effective&#xD;
      in reducing the quantity of bacteria (including MRSA)in a wound.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Limited recruitment&#xD;
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in bioburden (specifically MRSA)as assessed via quantitative cultures.</measure>
    <time_frame>10 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in the condition of the ulcer as judged by comparative photography and independent clinical assessment</measure>
    <time_frame>10 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>10 Days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">8</enrollment>
  <condition>Skin Ulcers</condition>
  <condition>Methicillin-resistant Staphylococcus Aureus Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric Oxide</intervention_name>
    <description>Gaseous nitric oxide (1%), delivered for 30 minutes per day for 3 consecutive days</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have given written informed consent&#xD;
&#xD;
          -  Must be â‰¥ 18 years of age and not of child bearing potential&#xD;
&#xD;
          -  Must have an ulcer in which the presence of MRSA has been identified, but which is not&#xD;
             clinically infected&#xD;
&#xD;
          -  Must have an ulcer size not to extend beyond the inner borders of the dressing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is a female of child bearing years or who could become pregnant&#xD;
&#xD;
          -  Is &lt; 18 years of age&#xD;
&#xD;
          -  Has an clinically infected skin ulcer&#xD;
&#xD;
          -  Has a ulcer that is being treated with a topical antimicrobial agent or has been&#xD;
             treated with a topical antimicrobial agent during 3 days prior to enrolment&#xD;
&#xD;
          -  Has been using systemic antibiotics during 7 days prior to enrolment into this study&#xD;
&#xD;
          -  Has an ulcer which is identified as malignant in origin (e.g. Marjolin's ulcer)&#xD;
&#xD;
          -  Has an ulcer size beyond the inner borders of the dressing&#xD;
&#xD;
          -  Is septic or has other signs of an invasive infection&#xD;
&#xD;
          -  Has used any investigational drug within 30 days preceding study participation.&#xD;
&#xD;
          -  Suffers from a condition, which, in the opinion of the Investigator, would compromise&#xD;
             his or her safety.&#xD;
&#xD;
          -  Suffers from a condition which, in the opinion of the Investigator, would compromise&#xD;
             the quality of the data.&#xD;
&#xD;
          -  Has a known allergy to any of the products that are part of this protocol&#xD;
&#xD;
          -  Suffers from a condition which, in the opinion of the Investigator, would seriously&#xD;
             interfere negatively with the normal parameters of immune response to an infection.&#xD;
&#xD;
          -  Is using any of the prohibited concomitant medications or treatments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Harding, MB ChB, MRGCP, FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Wound Healing, Cardiff University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Wound Healing, Cardiff University</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>November 12, 2008</study_first_submitted>
  <study_first_submitted_qc>November 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <last_update_submitted>November 28, 2011</last_update_submitted>
  <last_update_submitted_qc>November 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
    <mesh_term>Skin Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

